The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Harvard Bioscience Inc

Nasdaq: HBIO
Last

(U.S.) $6.10

Today's change-0.12 -1.93%
Updated April 27 2:56 PM -4GMT. Delayed by at least 15 minutes.
 

Harvard Bioscience Inc

Nasdaq: HBIO
Last

(U.S.) $6.10

Today's change-0.12 -1.93%
Updated April 27 2:56 PM -4GMT. Delayed by at least 15 minutes.

Harvard Bioscience Inc down (U.S.)$0.12

Harvard Bioscience Inc is sharply lower today, dropping (U.S.)$0.12 or 1.93% to (U.S.)$6.10. Shares have lost 3.94% over the last five days, but have gained 7.58% over the last year to date. This security has outperformed the S&P 500 by 24.32% during the last year.

Key company metrics

  • Open(U.S.) $6.22
  • Previous close(U.S.) $6.22
  • High(U.S.) $6.26
  • Low(U.S.) $6.04
  • Bid / Ask(U.S.) $6.10 / (U.S.) $6.11
  • YTD % change+7.58%
  • Volume55,602
  • Average volume (10-day)129,894
  • Average volume (1-month)150,601
  • Average volume (3-month)103,404
  • 52-week range(U.S.) $3.68 to (U.S.) $6.84
  • Beta1.17
  • Trailing P/E85.66×
  • P/E 1 year forward23.04×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.07
Updated April 27 2:56 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.45%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue30252726
Total other revenue--------
Total revenue30252726
Gross profit14111212
Total cost of revenue17141514
Total operating expense28242525
Selling / general / administrative10899
Research & development2111
Depreciation / amortization1111
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income2121
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax1111
Income after tax0111
Income tax, total1000
Net income0111
Total adjustments to net income--------
Net income before extra. items0111
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items0111
Inc. avail. to common incl. extra. items0111
Diluted net income0111
Dilution adjustment0------
Diluted weighted average shares32333333
Diluted EPS excluding extraordinary itemsvalue per share0.000.020.030.02
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.000.020.030.02